IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CURIGLIANO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 37.903
NA - Nord America 18.558
AS - Asia 17.360
SA - Sud America 1.323
OC - Oceania 404
AF - Africa 277
Continente sconosciuto - Info sul continente non disponibili 62
Totale 75.887
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 18.852
US - Stati Uniti d'America 17.681
CN - Cina 8.585
GB - Regno Unito 6.241
IT - Italia 3.562
SG - Singapore 2.667
SE - Svezia 2.215
RU - Federazione Russa 1.382
IN - India 1.308
FR - Francia 1.143
JP - Giappone 1.088
IE - Irlanda 1.053
BR - Brasile 904
ES - Italia 700
HK - Hong Kong 663
CA - Canada 603
ID - Indonesia 551
KR - Corea 530
NL - Olanda 462
TR - Turchia 462
AU - Australia 339
VN - Vietnam 324
TW - Taiwan 293
FI - Finlandia 270
CH - Svizzera 267
BE - Belgio 235
MX - Messico 222
AT - Austria 212
UA - Ucraina 192
PL - Polonia 191
DK - Danimarca 163
IR - Iran 137
GR - Grecia 135
PT - Portogallo 132
CO - Colombia 117
TH - Thailandia 107
NO - Norvegia 100
IL - Israele 98
PH - Filippine 97
RO - Romania 95
AR - Argentina 90
EU - Europa 88
PE - Perù 80
EG - Egitto 64
CL - Cile 63
NZ - Nuova Zelanda 63
MY - Malesia 57
CZ - Repubblica Ceca 56
PK - Pakistan 52
ZA - Sudafrica 50
HU - Ungheria 44
LB - Libano 38
SA - Arabia Saudita 37
JO - Giordania 33
AE - Emirati Arabi Uniti 32
HR - Croazia 32
KE - Kenya 31
TN - Tunisia 30
BG - Bulgaria 27
RS - Serbia 27
EC - Ecuador 26
AP - ???statistics.table.value.countryCode.AP??? 25
MA - Marocco 23
IQ - Iraq 22
SK - Slovacchia (Repubblica Slovacca) 21
BD - Bangladesh 20
UY - Uruguay 20
SI - Slovenia 18
UZ - Uzbekistan 17
KZ - Kazakistan 16
AM - Armenia 15
DZ - Algeria 15
NG - Nigeria 15
CY - Cipro 14
GE - Georgia 14
LT - Lituania 14
KG - Kirghizistan 12
A2 - ???statistics.table.value.countryCode.A2??? 10
AZ - Azerbaigian 9
CR - Costa Rica 9
SC - Seychelles 9
VE - Venezuela 9
ET - Etiopia 8
GH - Ghana 8
IS - Islanda 8
KW - Kuwait 8
MO - Macao, regione amministrativa speciale della Cina 8
BA - Bosnia-Erzegovina 7
CU - Cuba 7
DO - Repubblica Dominicana 7
LU - Lussemburgo 7
OM - Oman 7
PS - Palestinian Territory 7
BO - Bolivia 6
EE - Estonia 6
GT - Guatemala 6
MT - Malta 6
PA - Panama 6
PR - Porto Rico 6
QA - Qatar 6
Totale 75.849
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 17.253
Southend 5.084
Singapore 1.573
Chandler 1.457
Milan 1.337
Fairfield 1.221
Dublin 1.017
Princeton 976
Ashburn 944
Beijing 925
Houston 831
Council Bluffs 739
Wilmington 729
Shanghai 712
Redwood City 661
Seattle 659
Nanjing 555
Woodbridge 538
Ann Arbor 429
Cambridge 419
Santa Clara 404
Jakarta 399
Guangzhou 374
Bengaluru 364
Des Moines 348
Hangzhou 331
Dearborn 322
Xian 313
Tokyo 285
New York 261
Shenyang 255
Toronto 228
Jinan 215
Hong Kong 208
Seoul 193
Chengdu 188
Berlin 187
London 180
Los Angeles 179
Hyderabad 159
Helsinki 153
Taipei 150
Phoenix 148
Rome 147
Central District 142
Madrid 141
Changsha 139
San Diego 138
Boardman 134
São Paulo 132
Redmond 129
Nuremberg 128
Wuhan 126
Fuzhou 124
Istanbul 124
Paris 115
Zhengzhou 115
Nanchang 112
Munich 110
Tianjin 109
Barcelona 102
Hebei 97
Amsterdam 96
Vienna 94
Andover 93
Duncan 90
Silver Spring 88
Dong Ket 87
Shenzhen 86
Boston 83
Brussels 83
Chicago 81
Mountain View 80
Grafing 76
Jacksonville 76
Bogotá 75
Central 74
Hefei 73
Ottawa 68
Athens 66
Sydney 66
Mumbai 64
Kunming 61
Pune 61
San Francisco 61
Rho 59
San Jose 59
Washington 59
Buffalo 58
Florence 56
Lima 56
Bologna 55
Osaka 53
Turin 50
Jiaxing 49
Chongqing 48
Manchester 47
Harbin 46
Moscow 45
Warsaw 45
Totale 48.834
Salva come PNG Salva come JPEG
Nome #
Cetuximab for treating non-small cell lung cancer 2.013
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress 1.909
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 1.371
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) 1.245
Association of Breast Cancer Irradiation With Cardiac Toxic Effects : A Narrative Review 1.188
Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 1.181
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial 1.169
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases 1.102
Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors 1.051
Ribociclib plus letrozole in early breast cancer : a presurgical, window-of-opportunity study 813
Entinostat for the treatment of breast cancer 752
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 718
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan 672
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) 661
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 553
Progresses toward precision medicine in RET-altered solid tumors 523
Biologic therapy for advanced breast cancer : recent advances and future directions 466
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients with Cancer: A Review 448
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆ 433
Margetuximab for the treatment of HER2-positive metastatic breast cancer 419
Vaccine immunotherapy in breast cancer treatment: Promising, but still early 376
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer 368
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative 366
Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients 365
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 363
Report on the status of women occupying leadership roles in oncology 356
De-escalating and escalating treatments for early-stage breast cancer : the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 350
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer 343
Gender-related challenges facing oncologists: The results of the ESMO Women for Oncology Committee survey 331
Defining the immunogram of breast cancer: a focus on clinical trials 326
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) 315
Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma A C 310
Managing side effects of immune checkpoint inhibitors in breast cancer 295
Recent advances in triple negative breast cancer: the immunotherapy era 288
Lucitanib for the treatment of HRþ/HER2- Metastatic breast cancer : Results from the multicohort phase II FINESSE study 283
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) 275
Novel immune targets for the treatment of triple-negative breast cancer 258
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment 257
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 250
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 247
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis 244
New approaches for improving outcomes in breast cancer in Europe 242
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) 238
Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic 237
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs 229
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes 227
Expression of tumor-associated antigens in breast cancer subtypes 227
Antibody–drug conjugates in solid tumors: a look into novel targets 226
Tailoring therapies-improving the management of early breast cancer : St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 224
Alga : a cancer patient profiling tool to improve physician-patient communication. an analysis in breast cancer patients 223
Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study 222
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer 222
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial 215
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial 214
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer 214
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic : An International Collaborative Group 210
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers 210
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer 206
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis 205
Gemcitabine-induced systemic capillary leak syndrome 201
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies 201
Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in PtII complexes on human carcinoma cell lines: A comparative study with cisplatin 198
Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 197
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 195
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer 195
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial 189
Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations 189
Lessons from the first ecancer symposium on angiogenesis in gastric cancer 188
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 186
Edoxaban for Cancer-Associated Venous Thromboembolism 185
4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study 183
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors 181
QTc prolongation assessment in anticancer drug development : clinical and methodological issues 180
Dendritic cell sarcoma : an analytic overview of the literature and presentation of original five cases 179
Are all cyclin-dependent kinases 4/6 inhibitors created equal? 178
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare 176
Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study 176
Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer? 176
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 173
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 165
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug–drug interaction study 164
L’oncologia mutazionale del carcinoma polmonare: marcatori molecolari, farmaci, condizioni negoziali ed esperienze in centri di riferimento nazionale 163
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients : a Single-Institute Study 162
Homologous recombination deficiency in triple negative breast cancer 162
CDX-2 should be included in the work-up of patients with lung metastases from unknown primary 158
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 158
"Burned out" phenomenon of the testis in retroperitoneal seminoma 157
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 156
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy 155
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer 154
Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain 154
Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA 154
Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter 154
From precision medicine to cancer care through the immunome: Highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014 154
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 153
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 153
Should liver metastases of breast cancer be biopsied to improve treatment choice? 152
Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours 152
Tumour dormancy and clinical implications in breast cancer 152
Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors 152
Totale 36.254
Salva come PNG Salva come JPEG
Categoria #
all - tutte 191.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 191.266
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.235 0 0 0 0 0 0 0 0 776 785 361 313
2020/20218.796 407 397 503 428 745 887 497 552 1.293 822 1.165 1.100
2021/20228.787 723 770 623 612 759 663 776 597 907 580 538 1.239
2022/20239.040 1.094 714 970 714 893 1.497 350 588 820 321 654 425
2023/202420.391 564 693 587 695 1.399 1.214 2.869 2.525 1.406 2.471 2.962 3.006
2024/202516.522 2.774 2.782 2.239 2.315 1.293 1.104 889 1.902 1.224 0 0 0
Totale 79.105